These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 21270791)

  • 1. Hepatocyte proliferation and hepatitis C virus kinetics during treatment.
    Dahari H; Rong L; Layden TJ; Cotler SJ
    Clin Pharmacol Ther; 2011 Mar; 89(3):353-4. PubMed ID: 21270791
    [No Abstract]   [Full Text] [Related]  

  • 2. Understanding hepatitis C viral dynamics with direct-acting antiviral agents due to the interplay between intracellular replication and cellular infection dynamics.
    Guedj J; Neumann AU
    J Theor Biol; 2010 Dec; 267(3):330-40. PubMed ID: 20831874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bardoxolone methyl as a novel potent antiviral agent against hepatitis B and C viruses in human hepatocyte cell culture systems.
    Nio Y; Sasai M; Akahori Y; Okamura H; Hasegawa H; Oshima M; Watashi K; Wakita T; Ryo A; Tanaka Y; Hijikata M
    Antiviral Res; 2019 Sep; 169():104537. PubMed ID: 31207277
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Continued value in understanding viral kinetic decline during interferon-free therapy for HCV.
    Meissner EG
    Liver Int; 2015 Feb; 35(2):295-6. PubMed ID: 25424883
    [No Abstract]   [Full Text] [Related]  

  • 5. Curcumin against hepatitis C virus infection: spicing up antiviral therapies with 'nutraceuticals'?
    Pécheur EI
    Gut; 2014 Jul; 63(7):1035-7. PubMed ID: 24092864
    [No Abstract]   [Full Text] [Related]  

  • 6. Hepatitis C viral kinetic models.
    Herrmann E; Zeuzem S
    Cell Death Differ; 2003 Jan; 10 Suppl 1():S7-8. PubMed ID: 12655337
    [No Abstract]   [Full Text] [Related]  

  • 7. 3D cultured immortalized human hepatocytes useful to develop drugs for blood-borne HCV.
    Aly HH; Shimotohno K; Hijikata M
    Biochem Biophys Res Commun; 2009 Feb; 379(2):330-4. PubMed ID: 19103167
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mathematical modeling of HCV infection and treatment.
    Dahari H; Shudo E; Ribeiro RM; Perelson AS
    Methods Mol Biol; 2009; 510():439-53. PubMed ID: 19009281
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lycorine-derived phenanthridine downregulators of host Hsc70 as potential hepatitis C virus inhibitors.
    Chen D; Cai J; Yin J; Jiang J; Jing C; Zhu Y; Cheng J; Di Y; Zhang Y; Cao M; Li S; Peng Z; Hao X
    Future Med Chem; 2015; 7(5):561-70. PubMed ID: 25921398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cyclic phosphoramidates as prodrugs of 2'-C-methylcytidine.
    Meppen M; Pacini B; Bazzo R; Koch U; Leone JF; Koeplinger KA; Rowley M; Altamura S; Di Marco A; Fiore F; Giuliano C; Gonzalez-Paz O; Laufer R; Pucci V; Narjes F; Gardelli C
    Eur J Med Chem; 2009 Sep; 44(9):3765-70. PubMed ID: 19493593
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hepatitis C virus RNA kinetics: drug efficacy and the rate of HCV-infected cells loss.
    Dahari H; Perelson AS
    World J Gastroenterol; 2007 Jun; 13(21):3020-1. PubMed ID: 17589958
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment of hepatitis C virus infection with interferon and small molecule direct antivirals: viral kinetics and modeling.
    Rong L; Perelson AS
    Crit Rev Immunol; 2010; 30(2):131-48. PubMed ID: 20370626
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel drug resistance-associated substitutions against pibrentasvir emerged in genotype 1b hepatitis C virus-infected human hepatocyte transplanted mice.
    Ohya K; Imamura M; Teraoka Y; Uchida T; Fujino H; Nakahara T; Ono A; Murakami E; Yamauchi M; Kawaoka T; Miki D; Tsuge M; Abe-Chayama H; Hayes CN; Aikata H; Ishida Y; Tateno C; Song H; Miyayama Y; Hijikata M; Chayama K
    Biochem Biophys Res Commun; 2021 Jun; 559():78-83. PubMed ID: 33932902
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling hepatitis C virus kinetics: the relationship between the infected cell loss rate and the final slope of viral decay.
    Dahari H; Shudo E; Cotler SJ; Layden TJ; Perelson AS
    Antivir Ther; 2009; 14(3):459-64. PubMed ID: 19474480
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical evaluation of AT-527, a novel guanosine nucleotide prodrug with potent, pan-genotypic activity against hepatitis C virus.
    Good SS; Moussa A; Zhou XJ; Pietropaolo K; Sommadossi JP
    PLoS One; 2020; 15(1):e0227104. PubMed ID: 31914458
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aloperine inhibits hepatitis C virus entry into cells by disturbing internalisation from endocytosis to the membrane fusion process.
    Lv XQ; Zou LL; Tan JL; Li H; Li JR; Liu NN; Dong B; Song DQ; Peng ZG
    Eur J Pharmacol; 2020 Sep; 883():173323. PubMed ID: 32622669
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Elimination of hepatitis C virus from hepatocytes by a selective activation of therapeutic molecules.
    Wen X; Abe T; Kukihara H; Taguwa S; Mori Y; Tani H; Kato N; Suzuki T; Tatsumi M; Moriishi K; Matsuura Y
    PLoS One; 2011 Jan; 6(1):e15967. PubMed ID: 21253612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phosphoramidate prodrugs of 2'-C-methylcytidine for therapy of hepatitis C virus infection.
    Gardelli C; Attenni B; Donghi M; Meppen M; Pacini B; Harper S; Di Marco A; Fiore F; Giuliano C; Pucci V; Laufer R; Gennari N; Marcucci I; Leone JF; Olsen DB; MacCoss M; Rowley M; Narjes F
    J Med Chem; 2009 Sep; 52(17):5394-407. PubMed ID: 19725579
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C Virus.
    Vausselin T; Séron K; Lavie M; Mesalam AA; Lemasson M; Belouzard S; Fénéant L; Danneels A; Rouillé Y; Cocquerel L; Foquet L; Rosenberg AR; Wychowski C; Meuleman P; Melnyk P; Dubuisson J
    J Virol; 2016 Oct; 90(19):8422-34. PubMed ID: 27412600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Subgenomic replications of hepatitis C virus (HCV): new possibilities for hepatitis C prophylaxis and treatment].
    Puig-Basagoiti F; Sáiz JC
    Gastroenterol Hepatol; 2001 Dec; 24(10):506-10. PubMed ID: 11730621
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.